A biotechnology company has been formed with the explicit goal of creating pharmaceuticals that mimic the age-retarding effects of caloric restriction.

The company, BioMarker Pharmaceuticals, announced its goals yesterday.

“BioMarker will pursue research in this area with a goal of developing drugs that slow the aging process and extend youthfulness while also preventing and treating aging-related diseases such as cancer, diabetes and cardiovascular disorders,” says Dr. Xi Zhao-Wilson, BioMarker’s founder, director and chief executive officer.